The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5-HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B

Psychopharmacology

Volumn 213, Issue 2-3, 2011, Pages 393-401

  Scarlota, Laura C ^a   Harvey, John A ^a   Aloyo, Vincent J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

5 HT2A receptors; 5 HT2C receptors; D1 receptors; D2 receptors; Dopamine; Serotonin

Indexed keywords

1(2,5 DIMETHOXY 4 IODOPHENYL) 2 AMINOPROPANE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; EPLIVANSERIN; KETANSERIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BODY MOVEMENT; CONTROLLED STUDY; HEAD MOVEMENT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECEPTOR BINDING; RECEPTOR BLOCKING;

AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; FLUOROBENZENES; HEAD MOVEMENTS; MALE; PHENOLS; RABBITS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 79952489193     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1928-2     Document Type: Article

References (28)

1. Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296-320 (Pubitemid 46149046)
2. Bonaccorso S, Meltzer HY, Li Z, Dai J, Alboszta AR, Ichikawa J (2002) SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 27(3):430-441 (Pubitemid 35253790)
3. Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, Artigas F (2005) The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95(6):1597-1607 (Pubitemid 41804057)
4. Dave KD, Harvey JA, Aloyo VJ (2002) A novel behavioral model that discriminates between 5-HT2A and 5-HT2C receptor activation. Pharmacol Biochem Behav 72(1-2):371-378 (Pubitemid 34251347)
5. De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24(13):3235-3241 (Pubitemid 38451889)
6. Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91 (2):587-597 (Pubitemid 29193268)
7. Fozard JR, Palfreyman MG (1979) Metoclopramide antagonism of 5-hydroxytryptophan-induced "wet-dog" shake behaviour in the rat. Naunyn Schmiedebergs Arch Pharmacol 307(2):135-142
8. Gewirtz JC, Marek GJ (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharm 23:569-576
9. Gobert A, Millan MJ (1999) Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38(2):315-317 (Pubitemid 29073553)
10. Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan M (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. Synapse 36(3):205-221 (Pubitemid 30252995)
11. Graeff FG, Netto CF, Zangrossi H Jr (1998) The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 23 (2):237-246 (Pubitemid 29011625)
12. Green AR, Johnson P, Nimgaonkar VL (1983) Increased 5-HT2 receptor number in brain as a probable explanation for the enhanced 5-hydroxytryptamine- mediated behaviour following repeated electroconvulsive shock administration to rats. Br J Pharmacol 80(1):173-177 (Pubitemid 13000893)
13. Hackler EA, Turner GH, Gresch PJ, Sengupta S, Deutch AY, Avison MJ, Gore JC, Sanders-Bush E (2007) 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J Pharmacol Exp Ther 320(3):1023-1029 (Pubitemid 46294062)
14. Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A, Blackburn TP (1994) In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 111(3):797-802
15. Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, Blackburn TP (1996) In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117(3):427-434
16. Millan MJ, Dekeyne A, Gobert A (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37(7):953-955
17. Mora PO, Netto CF, Graeff FG (1997) Role of 5-HT2A and 5-HT2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol Biochem Behav 58(4):1051-1057 (Pubitemid 28108215)
18. Nic Dhonnchadha BA, Ripoll N, Clenet F, Hascoet M, Bourin M (2005) Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test. Psychopharmacology (Berl) 179(2):418-429 (Pubitemid 40569045)
19. Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS (2006) Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31(2):265-277 (Pubitemid 43113392)
20. Rinaldi-Carmona M, Congy C, Santucci V, Simiand J, Gautret B, Neliat G, Labeeuw B, Le Fur G, Soubrie P, Breliere JC (1992) Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist. J Pharmacol Exp Ther 262(2):759-768
21. Ripoll N, Hascoet M, Bourin M (2006) Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behav Brain Research 166(1):131-139 (Pubitemid 41677369)
22. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3(4):353-359 (Pubitemid 38499762)
23. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2, 5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273(1):101-112
24. Simansky KJ, Baker G, Kachelries WJ, Hood H, Romano AG, Harvey JA (1998) Prenatal exposure to cocaine reduces dopaminergic D1-mediated motor function but spares the enhancement of learning by amphetamine in rabbits. Ann N Y Acad Sci 846:375-378 (Pubitemid 28365415)
25. Stiedl O, Misane I, Koch M, Pattij T, Meyer M, Ogren SO (2007) Activation of the brain 5-HT2C receptors causes hypolocomotion without anxiogenic-like cardiovascular adjustments in mice. Neuropharmacology 52(3):949-957 (Pubitemid 46227482)
26. Wood MD (2003) Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders. Curr Drug Targets CNS Neurol Disord 2(6):383-387
27. Wood MD, Wren PB (2008) Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders. Prog Brain Res 172:213-230
28. Yonezawa A, Yoshizumi M, Ebiko M, Ise SN, Watanabe C, Mizoguchi H, Kimura Y, Sakurada S (2008) Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes. Pharmacol Biochem Behav 88(4):367-373 (Pubitemid 350266778)